These data imply that, in contrast to the patterns observed with the malignancies previously mentioned, hepatocellular cancer may be an example of a cancer in which the downregulation of PCSK9 may have adverse effects. The gene discussed is PCSK9; the disease is hepatocellular carcinoma.